KIRA6 is an Effective and Versatile Mast Cell Inhibitor of IgE‐mediated Activation
European Journal of Immunology · 2025
DOI: 10.1002/eji.202451348 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Veronika Wunderle und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Molecular Immunology, Medical Faculty, RWTH Aachen University, Aachen, Germany. Hauptthemen laut MEDLINE: Mast Cells, Immunoglobulin E. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German-Israeli Foundation for Scientific Research and Development.
Abstract (Originalsprache)
Mast cell (MC)‐driven allergic diseases are constantly expanding and require the development of novel pharmacological MC stabilizers. Allergen/antigen (Ag)‐triggered activation via crosslinking of the high‐affinity receptor for IgE (FcεRI) is fundamentally regulated by SRC family kinases, for example, LYN and FYN, exhibiting positive and negative functions. We report that KIRA6, an inhibitor for the endoplasmic reticulum stress sensor IRE1α, suppresses IgE‐mediated MC activation by inhibiting both LYN and FYN. KIRA6 attenuates Ag‐stimulated early signaling and effector functions such as degranulation and proinflammatory cytokine production/secretion in murine bone marrow‐derived MCs. Moreover, Ag‐triggered bronchoconstriction in an ex vivo model and IgE‐mediated stimulation of human MCs were repressed by KIRA6. The interaction of KIRA6 with three MC‐relevant tyrosine kinases, LYN, FYN, and KIT, and the potential of KIRA6 structure as a pharmacophore for the development of respective single‐, dual‐, or triple‐specificity inhibitors, was evaluated by homology modeling and molecular dynamics simulations. We found that KIRA6 particularly strongly binds the inactive state of LYN, FYN, and KIT with comparable affinities. In conclusion, our data suggest that the chemical structure of KIRA6 as a pharmacophore can be further developed to obtain an effective MC stabilizer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry and Molecular Immunology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- The School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel.
- Institute for Advanced Simulation, Jülich Supercomputing Centre, Forschungszentrum Jülich GmbH, Jülich, Germany.
- Department of Hematological Biology, Pitié-Salpêtrière Charles-Foix Hospital, AP-HP Sorbonne University, Paris, France.
- Institute of Pharmacology and Toxicology, Medical Faculty, RWTH Aachen University, Aachen, Germany.
ORCID-Profile: Veronika Wunderle
Förderung
- German-Israeli Foundation for Scientific Research and Development
Zitieren
APA
Wunderle, V., Wilhelm, T., Boukeileh, S., Goßen, J., Margreiter, M. A., Sakurov, R., Capellmann, S., Schwoerer, M., Ahmed, N., Bronneberg, G., Arock, M., Martin, C., Schubert, T., Levi-Schaffer, F., Rossetti, G., Tirosh, B., & Huber, M. (2025). KIRA6 is an Effective and Versatile Mast Cell Inhibitor of IgE‐mediated Activation. European Journal of Immunology. https://doi.org/10.1002/eji.202451348
Vancouver
Wunderle V, Wilhelm T, Boukeileh S, Goßen J, Margreiter MA, Sakurov R, et al. KIRA6 is an Effective and Versatile Mast Cell Inhibitor of IgE‐mediated Activation. European Journal of Immunology. 2025. doi:10.1002/eji.202451348
BibTeX
@article{Wunderle2025,
author = {Wunderle, Veronika and Wilhelm, Thomas and Boukeileh, Shatha and Goßen, Jonas and Margreiter, Michael A and Sakurov, Roman and Capellmann, Sandro and Schwoerer, Maike and Ahmed, Nabil and Bronneberg, Gina and Arock, Michel and Martin, Christian and Schubert, Thomas and Levi-Schaffer, Francesca and Rossetti, Giulia and Tirosh, Boaz and Huber, Michael},
title = {KIRA6 is an Effective and Versatile Mast Cell Inhibitor of IgE‐mediated Activation},
journal = {European Journal of Immunology},
year = {2025},
doi = {10.1002/eji.202451348}
}
EUVIMED